Back

Melanoma and Sarcoma Center - Clinical Trials

Specialty Cancer Centers

New Patient Appointment

321.841.8470

Clinical Trials

  • A Phase 1b/3, Multicenter Trial of Talimogene Laherparepvec

    Phase 1b Subjects will be treated with talimogene laherparepvec until all injectable tumors have disappeared, disease progression per modified Immune-Related Response Criteria (irRC), or intolerance of study treatment, up to a maximum of 24 months of study treatment. Subjects will be treated with MK-3475 (pembrolizumab) until complete response (CR) disease progression per irRC, or intolerance of study treatment, up to a maximum of 24 months of study treatment. In Phase 3, Subjects will be treated with talimogene laherparepvec plus pembrolizumab(arm 1) or placebo plus pembrolizumab (arm 2) until 24 months from the date of the first dose of pembrolizumab or end of treatment due to disappearance of injectable lesions, complete response, disease progression per irRC-RECIST or intolerance of study treatment.

  • Intermittent Vs Continuous Dosing of Dabrafenib and Trametinib

    The primary objective of this study is to compare progression-free survival with intermittent dosing and continuous dosing of dabrafenib and trametinib among patients with metastatic BRAFV600E/K mutant melanoma.

  • Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab

    •OS rate, defined as the proportion of patients alive after 2 years of follow-up time [ Time Frame: 2 years ] [ Designated as safety issue: No ] Will be estimated and compared between the two arms using the Fisher's exact test based on two-sided overall type I error rate of 0.05 adjusting for two-interim analysis. Distribution will be estimated using the Kaplan-Meier method.

  • A Randomized Phase II Trial of Intermittent Versus Continuous Dos

    The primary objective of this study is to compare progression-free survival with intermittent dosing and continuous dosing of dabrafenib and trametinib among patients with metastatic BRAFV600E/K mutant melanoma.

  • EAP-Combination Yervoy and Opdivo

    The primary objective of this study is to provide treatment with nivolumab for the combination with ipilimumab (Yervoy) to subjects who are anti-CTLA-4 and anti-PD-1 treatment-naive and have unresectable or metastatic melanoma. Safety data will be collected and reported according to health authority regulations and BMS regulations. QoL data will be measured using the EORTC QLQ-C30. Additionally, survival data collection (up to 5 years following the subject¡¦s start of treatment with nivolumab) is recommended to be part of the subject¡¦s follow up and will be summarized or listed, depending on the extent of such collected data

  • A Phase 3, Study of Adjuvant Immunotherapy with Nivolumab

    To compare the efficacy, as measured by recurrence free survival (RFS), provided by nivolumab versus ipilimumab in subjects with completely resected Stage IIIb/c or Stage IV NED melanoma who are at high-risk for recurrence.

  • Melanoma Antigen Vaccine Immunotherapy Study

    The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients who have undergone surgery.